Future challenges in the elimination of bacterial meningitis

Vaccine

Volumn 30, Issue SUPPL. 2, 2012, Pages

  Bottomley, Matthew J ^a   Serruto, Davide ^a   Sáfadi, Marco Aurélio Palazzi ^b   Klugman, Keith P ^c,d  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b Santa Casa de Sao Paulo School of Medicine   (Brazil)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Meningococcus; Streptococcus; Surveillance; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; MENINGITIS VACCINE; PNEUMOCOCCUS VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; STREPTOCOCCUS VACCINE;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL MENINGITIS; BACTERIAL VIRULENCE; BACTERIUM DETECTION; DRUG EFFICACY; ESCHERICHIA COLI; GROUP B STREPTOCOCCAL MENINGITIS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS MENINGITIS; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; MENINGOCOCCOSIS; MINIMAL RESIDUAL DISEASE; MORBIDITY; MORTALITY; MULTILOCUS SEQUENCE TYPING; MYCOBACTERIUM TUBERCULOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

BIOMEDICAL RESEARCH; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNIZATION PROGRAMS; MENINGITIS, BACTERIAL;

EID: 84861157044     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.099     Document Type: Article

References (101)

1. Thigpen M.C., Whitney C.G., Messonnier N.E., Zell E.R., Lynfield R., Hadler J.L., et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011, 364(May (21)):2016-2025.
2. Schuchat A., Robinson K., Wenger J.D., Harrison L.H., Farley M., Reingold A.L., et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997, 337(October (14)):970-976.
3. Gold R. Epidemiology of bacterial meningitis. Infect Dis Clin North Am 1999, 13(September (3)):515-525.
4. Tan L.K., Carlone G.M., Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010, 362(April (16)):1511-1520.
5. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(June (Suppl. 2)):B51-B63.
6. Furyk J.S., Swann O., Molyneux E. Systematic review: neonatal meningitis in the developing world. Trop Med Int Health 2011, 16(June (6)):672-679.
7. Melin P. Neonatal group B streptococcal disease: from pathogenesis to preventive strategies. Clin Microbiol Infect 2011, 17(September (9)):1294-1303.
8. Sadarangani M., Pollard A.J. Serogroup B meningococcal vaccines - an unfinished story. Lancet Infect Dis 2010, 10(February (2)):112-124.
9. Safadi M.A., Cintra O.A. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res 2010, 32(April (3)):263-271.
10. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995, 13(June (9)):821-829.
11. Martin D.R., Walker S.J., Baker M.G., Lennon D.R. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 1998, 177(February (2)):497-500.
12. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338(November (8775)):1093-1096.
13. Stuart J.M., Cartwright K.A., Jones D.M., Noah N.D., Wall R.J., Blackwell C.C., et al. An outbreak of meningococcal disease in Stonehouse: planning and execution of a large-scale survey. Epidemiol Infect 1987, 99(December (3)):579-589.
14. Sacchi C.T., Fukasawa L.O., Goncalves M.G., Salgado M.M., Shutt K.A., Carvalhanas T.R., et al. Incorporation of real-time PCR into routine public health surveillance of culture negative bacterial meningitis in Sao Paulo, Brazil. PLoS One 2011, 6(6):e20675.
15. Saha S.K., Darmstadt G.L., Yamanaka N., Billal D.S., Nasreen T., Islam M., et al. Rapid diagnosis of pneumococcal meningitis: implications for treatment and measuring disease burden. Pediatr Infect Dis J 2005, 24(December (12)):1093-1098.
16. Afifi S., Wasfy M.O., Azab M.A., Youssef F.G., Pimentel G., Graham T.W., et al. Laboratory-based surveillance of patients with bacterial meningitis in Egypt (1998-2004). Eur J Clin Microbiol Infect Dis 2007, 26(May (5)):331-340.
17. Wang X., Mair R., Hatcher C., Theodore M.J., Edmond K., Wu H.M., et al. Detection of bacterial pathogens in Mongolia meningitis surveillance with a new real-time PCR assay to detect Haemophilus influenzae. Int J Med Microbiol 2011, 301(April (4)):303-309.
18. Chanteau S., Sidikou F., Djibo S., Moussa A., Mindadou H., Boisier P. Scaling up of PCR-based surveillance of bacterial meningitis in the African meningitis belt: indisputable benefits of multiplex PCR assay in Niger. Trans R Soc Trop Med Hyg 2006, 100(July (7)):677-680.
19. CDC MMWR 2008, 57(46):1252-1255.
20. Adegbola R.A., Secka O., Lahai G., Lloyd-Evans N., Njie A., Usen S., et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005, 366(July (9480)):144-150.
21. WHO Statistics on Haemophilus influenzae Type b: Global Immunization 1990-2010 2011.
22. von Gottberg A., Cohen C., Whitelaw A., Chhagan M., Flannery B., Cohen A.L., et al. Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009. Vaccine 2011, November.
23. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360(January (3)):244-256.
24. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(January (1)):32-41.
25. Fitzwater S.P., Watt J.P., Levine O.S., Santosham M. Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries. Hum Vaccin 2010, 6(October (10)):810-818.
26. Ojo L.R., O'Loughlin R.E., Cohen A.L., Loo J.D., Edmond K.M., Shetty S.S., et al. Global use of Haemophilus influenzae type b conjugate vaccine. Vaccine 2010, 28(October (43)):7117-7122.
27. Adams W.G., Deaver K.A., Cochi S.L., Plikaytis B.D., Zell E.R., Broome C.V., et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993, 269(January (2)):221-226.
28. Watt J.P., Levine O.S., Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002. J Pediatr 2003, 143(December (6 Suppl.)):S163-S187.
29. Jafari H.S., Adams W.G., Robinson K.A., Plikaytis B.D., Wenger J.D. Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus influenzae study group. Am J Public Health 1999, 89(March (3)):364-368.
30. Lee Y.C., Kelly D.F., Yu L.M., Slack M.P., Booy R., Heath P.T., et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 2008, 46(January (2)):186-192.
31. Bryant K.A., Block S.L., Baker S.A., Gruber W.C., Scott D.A. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010, 125(May (5)):866-875.
32. Prymula R., Schuerman L. 10-Valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009, 8(November (11)):1479-1500.
33. Klugman K.P. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect Dis 2001, 1(September (2)):85-91.
34. Giefing C., Meinke A.L., Hanner M., Henics T., Bui M.D., Gelbmann D., et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 2008, 205(January (1)):117-131.
35. Gianfaldoni C., Censini S., Hilleringmann M., Moschioni M., Facciotti C., Pansegrau W., et al. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun 2007, 75(February (2)):1059-1062.
36. Moschioni M., Donati C., Muzzi A., Masignani V., Censini S., Hanage W.P., et al. Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related. J Infect Dis 2008, 197(March (6)):888-896.
37. Serruto D., Serino L., Masignani V., Pizza M. Genome-based approaches to develop vaccines against bacterial pathogens. Vaccine 2009, 27(May (25-26)):3245-3250.
38. van Gils E.J., Hak E., Veenhoven R.H., Rodenburg G.D., Bogaert D., Bruin J.P., et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One 2011, 6(6):e20229.
39. Dull P., Rosenstein N. Meningococcal disease and vaccines. Pediatr Ann 2001, 30(June (6)):358-361.
40. Feavers I.M., Pizza M. Meningococcal protein antigens and vaccines. Vaccine 2009, 27(June (Suppl. 2)):B42-B50.
41. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364(June (24)):2293-2304.
42. Anderson A.S., Jansen K.U., Eiden J. New frontiers in meningococcal vaccines. Expert Rev Vaccines 2011, 10(May (5)):617-634.
43. Bai X., Findlow J., Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011, 11(July (7)):969-985.
44. Mothibeli K.M., du Plessis M., von Gottberg A., Murphy E., Hoiseth S.K., Zlotnick G., et al. Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine 2011, 29(March (11)):2187-2192.
45. Wang X., Cohn A., Comanducci M., Andrew L., Zhao X., Macneil J.R., et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011, 29(June (29-30)):4739-4744.
46. Lucidarme J., Newbold L.S., Findlow J., Gilchrist S., Gray S.J., Carr A.D., et al. Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP. Clin Vaccine Immunol 2011, 18(February (2)):194-202.
47. Donnelly J., Medini D., Boccadifuoco G., Biolchi A., Ward J., Frasch C., et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010, October.
48. Rossi I.A., Zuber P.L., Dumolard L., Walker D.G., Watt J. Introduction of Hib vaccine into national immunization programmes: a descriptive analysis of global trends. Vaccine 2007, 25(October (41)):7075-7080.
49. Shearer J.C., Stack M.L., Richmond M.R., Bear A.P., Hajjeh R.A., Bishai D.M. Accelerating policy decisions to adopt Haemophilus influenzae type B vaccine: a global, multivariable analysis. PLoS Med 2010, 7(March (3)):e1000249.
50. Danovaro-Holliday M.C., Garcia S., de Quadros C., Tambini G., Andrus J.K. Progress in vaccination against Haemophilus influenzae type b in the Americas. PLoS Med 2008, 5(April (4)):e87.
51. Aristegui J., Usonis V., Coovadia H., Riedemann S., Win K.M., Gatchalian S., et al. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int J Infect Dis 2003, 7(June (2)):143-151.
52. Johnson N.G., Ruggeberg J.U., Balfour G.F., Lee Y.C., Liddy H., Irving D., et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis 2006, 12(June (6)):937-941.
53. McVernon J., Andrews N., Slack M.P., Ramsay M.E. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003, 361(May (9368)):1521-1523.
54. Platonov A.E., Griffiths U.K., Voeykova M.V., Platonova O.V., Shakhanina I.L., Chistyakova G.G., et al. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation. Vaccine 2006, 24(March (13)):2367-2376.
55. Madhavi Y. Vaccine policy in India. PLoS Med 2005, 2(May (5)):e127.
56. LaForce F.M., Konde K., Viviani S., Preziosi M.P. The meningitis vaccine project. Vaccine 2007, 25(September (Suppl. 1)):A97-A100.
57. Boisier P., Nicolas P., Djibo S., Taha M.K., Jeanne I., Mainassara H.B., et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007, 44(March (5)):657-663.
58. Djibo S., Nicolas P., Alonso J.M., Djibo A., Couret D., Riou J.Y., et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop Med Int Health 2003, 8(December (12)):1118-1123.
59. Mutonga D.M., Pimentel G., Muindi J., Nzioka C., Mutiso J., Klena J.D., et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Am J Trop Med Hyg 2009, 80(April (4)):619-624.
60. Broker M. Indirect effects by meningococcal vaccines: herd protection versus herd immunity. Hum Vaccin 2011, 7(August (8)).
61. Rodgers G.L., Klugman K.P. The future of pneumococcal disease prevention. Vaccine 2011, 29(September (Suppl. 3)):C43-C48.
62. Clemens J., Shin S., Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect Dis 2011, 11(June (6)):482-487.
63. Jefferies J.M., Clarke S.C., Webb J.S., Kraaijeveld A.R. Risk of Red Queen dynamics in pneumococcal vaccine strategy. Trends Microbiol 2011, 19(August (8)):377-381.
64. Pajon R., Fergus A.M., Koeberling O., Caugant D.A., Granoff D.M. Meningococcal factor h binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 2011, 5(September (9)):e1302.
65. Scarselli M., Arico B., Brunelli B., Savino S., Di Marcello F., Palumbo E., et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 2011, 3(July (91)):91ra62.
66. Trivedi K., Tang C.M., Exley R.M. Mechanisms of meningococcal colonisation. Trends Microbiol 2011, 19(September (9)):456-463.
67. Berkley J.A., Lowe B.S., Mwangi I., Williams T., Bauni E., Mwarumba S., et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005, 352(January (1)):39-47.
68. English M., Ngama M., Musumba C., Wamola B., Bwika J., Mohammed S., et al. Causes and outcome of young infant admissions to a Kenyan district hospital. Arch Dis Child 2003, 88(May (5)):438-443.
69. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349(October (14)):1341-1348.
70. Madhi S.A., Adrian P., Kuwanda L., Cutland C., Albrich W.C., Klugman K.P. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae - and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization - in HIV-infected and HIV-uninfected children. J Infect Dis 2007, 196(December (11)):1662-1666.
71. Johri A.K., Paoletti L.C., Glaser P., Dua M., Sharma P.K., Grandi G., et al. Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol 2006, 4(December (12)):932-942.
72. Baker C.J., Rench M.A., McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003, 21(July (24)):3468-3472.
73. Palmeiro J.K., De Carvalho N.S., Botelho A.C., Fracalanzza S.E., Madeira H.M., Dalla-Costa L.M. Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention. Vaccine 2011, 29(May (21)):3729-3730.
74. Cozzi R., Telford J.L., Maione D. Towards the development of a universal vaccine against group B Streptococcus 2011, Caister Academic Press, Norfolk, UK, p. 289-302.
75. Maione D., Margarit I., Rinaudo C.D., Masignani V., Mora M., Scarselli M., et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005, 309(July (5731)):148-150.
76. Margarit I., Rinaudo C.D., Galeotti C.L., Maione D., Ghezzo C., Buttazzoni E., et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 2009, 199(January (1)):108-115.
77. Kuruvilla K.A., Thomas N., Jesudasan M.V., Jana A.K. Neonatal Group B Streptococcal bacteraemia in India: ten years' experience. Acta Paediatr 1999, 88(September (9)):1031-1032.
78. Bentlin M.R., Ferreira G.L., Rugolo L.M., Silva G.H., Mondelli A.L., Rugolo A. Neonatal meningitis according to the microbiological diagnosis: a decade of experience in a tertiary center. Arq Neuropsiquiatr 2010, 68(December (6)):882-887.
79. Krebs V.L., Taricco L.D. Risk factors for bacterial meningitis in the newborn. Arq Neuropsiquiatr 2004, 62(September (3A)):630-634.
80. Heath P.T. An update on vaccination against group B streptococcus. Expert Rev Vaccines 2011, 10(May (5)):685-694.
81. Dye C., Scheele S., Dolin P., Pathania V., Raviglione M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999, 282(August (7)):677-686.
82. Gandhi N.R., Moll A., Sturm A.W., Pawinski R., Govender T., Lalloo U., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368(November (9547)):1575-1580.
83. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367(April (9517)):1173-1180.
84. Skeiky Y.A., Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006, 4(June (6)):469-476.
85. Checkley A.M., McShane H. Tuberculosis vaccines: progress and challenges. Trends Pharmacol Sci 2011, July.
86. Centers for Disease Control and Prevention CDC. Extrapulmonary tuberculosis cases and percentages by site of diesase: reporting areas. 2005.
87. Lu T.H., Huang R.M., Chang T.D., Tsao S.M., Wu T.C. Tuberculosis mortality trends in Taiwan: a resurgence of non-respiratory tuberculosis. Int J Tuberc Lung Dis 2005, 9(January (1)):105-110.
88. Escosteguy C.C., Medronho Rde A., Madruga R., Dias H.G., Braga R.C., Azevedo O.P. [Epidemiologic surveillance and evaluation of meningitis hospital care]. Rev Saude Publica 2004, 38(October (5)):657-663.
89. Rappuoli R., Aderem A.A. 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011, 473(May (7348)):463-469.
90. Cripps A.W., Otczyk D.C. Prospects for a vaccine against otitis media. Expert Rev Vaccines 2006, 5(August (4)):517-534.
91. Bluestone C.D. Clinical course, complications and sequelae of acute otitis media. Pediatr Infect Dis J 2000, 19(May (5 Suppl.)):S37-S46.
92. Jin Z., Romero-Steiner S., Carlone G.M., Robbins J.B., Schneerson R. Haemophilus influenzae type a infection and its prevention. Infect Immun 2007, 75(June (6)):2650-2654.
93. Wang K.W., Chang W.N., Shih T.Y., Huang C.R., Tsai N.W., Chang C.S., et al. Infection of cerebrospinal fluid shunts: causative pathogens, clinical features, and outcomes. Jpn J Infect Dis 2004, 57(April (2)):44-48.
94. McClelland S., Hall W.A. Postoperative central nervous system infection: incidence and associated factors in 2111 neurosurgical procedures. Clin Infect Dis 2007, 45(July (1)):55-59.
95. Tavares W.M., Machado A.G., Matushita H., Plese J.P. CSF markers for diagnosis of bacterial meningitis in neurosurgical postoperative patients. Arq Neuropsiquiatr 2006, 64(September (3A)):592-595.
96. Ulsenheimer M.M., Antoniuk S.A., Santos L.H., Ceccatto M.P., Silveira A.E., Ruiz A.P., et al. Myelomeningocele: a Brazilian University Hospital experience. Arq Neuropsiquiatr 2004, 62(December (4)):963-968.
97. McCormick D.W., Molyneux E.M. Bacterial meningitis and Haemophilus influenzae type b conjugate vaccine, Malawi. Emerg Infect Dis 2011, 17(April (4)):688-690.
98. Micoli F., Rondini S., Pisoni I., Proietti D., Berti F., Costantino P., et al. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 2011, 29(January (4)):712-720.
99. Mai N.T., Hoa N.T., Nga T.V., Linh le D., Chau T.T., Sinh D.X., et al. Streptococcus suis meningitis in adults in Vietnam. Clin Infect Dis 2008, 46(March (5)):659-667.
100. Wertheim H.F., Nguyen H.N., Taylor W., Lien T.T., Ngo H.T., Nguyen T.Q., et al. Streptococcus suis, an important cause of adult bacterial meningitis in northern Vietnam. PLoS One 2009, 4(6):e5973.
101. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103(July (29)):10834-10839.